(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.


Figure 8


Fig. 8. FGF functions through SHP-2 to maintain the cardiac lineage. (A) Whole-mount in situ hybridization for Tbx5, Tbx20 and Nkx2.5 or whole-mount immunostaining for MHC (red) performed on explants treated with DMSO or the FGFR1 inhibitor SU5402. (B) Explants isolated from uninjected (control) or SHP-2 N308D-injected Xenopus embryos cultured in DMSO or SU5402 and analyzed by in situ hybridization for the cardiac markers Nkx2.5 and Tbx5. (C,D) Western blot analysis of DMSO-, NSC-87877-(C) or SU5402-(D) treated explants for phosphorylated and total ERK; {alpha}-tubulin was used as a loading control. (E) Explants were cut at stage 22 and then incubated in either modified Barth's solution (MBS) or SU5402 until stage 35. Either endogenous SHP-2 was immunoprecipitated (IP) or explants were lysed (IB) and western analysis performed as in Fig. 7B.